Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
Pembrolizumab with chemotherapy (immunochemotherapy) has shown encouraging overall survival (OS) benefits in non-squamous mNSCLC, as demonstrated by the KEYNOTE-189 trial. However, randomised controlled trials may not fully capture the diversity of real-world patients. This study aims to evaluate im...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
05 Feb 2025
|
| In: |
Pulmonology
Year: 2025, Volume: 31, Issue: 1, Pages: 1-11 |
| ISSN: | 2531-0437 |
| DOI: | 10.1080/25310429.2025.2457856 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1080/25310429.2025.2457856
|
| Author Notes: | Irina Surovtsova, Felix J.F. Herth, Daria B. Kokh and Philipp Morakis |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1931722919 | ||
| 003 | DE-627 | ||
| 005 | 20250724123232.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250724s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/25310429.2025.2457856 |2 doi | |
| 035 | |a (DE-627)1931722919 | ||
| 035 | |a (DE-599)KXP1931722919 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Surovtsova, Irina |e VerfasserIn |0 (DE-588)1100197281 |0 (DE-627)859171175 |0 (DE-576)469551259 |4 aut | |
| 245 | 1 | 0 | |a Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC |b Real-world evidence |c Irina Surovtsova, Felix J.F. Herth, Daria B. Kokh and Philipp Morakis |
| 264 | 1 | |c 05 Feb 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 24.07.2025 | ||
| 520 | |a Pembrolizumab with chemotherapy (immunochemotherapy) has shown encouraging overall survival (OS) benefits in non-squamous mNSCLC, as demonstrated by the KEYNOTE-189 trial. However, randomised controlled trials may not fully capture the diversity of real-world patients. This study aims to evaluate immunochemotherapy outcomes in a real-world setting, including subgroups underrepresented in the KEYNOTE-189 trial. Patients diagnosed with non-squamous mNSCLC 2011-2022 and recorded in Cancer Registry Database of the German Federal State Baden-Württemberg (BWCR), were analysed. OS was assessed using Kaplan-Meier and multivariable Cox models, adjusted for major clinical parameters. Results were compared with KEYNOTE-189. Among 2630 eligible cases, 1314 patients received chemotherapy alone and 1316 received immunochemotherapy. Median OS (mOS) was 14.1 months (95%CI: 13.1-15.4) for immunochemotherapy and 10.4 months (95%CI: 9.7-11.2) for chemotherapy alone, with an HR of 0.7 (95%CI: 0.64-0.77). A significant benefit was seen in M1c stage (HR 0.7, 95%CI: 0.63-0.79). No significant OS improvement was observed in patients with ECOG 2-3 or bone metastases. This real-world evidence suggests that immunochemotherapy generally improves OS in mNSCLC. Subgroup analysis showed no survival benefit for patients with ECOG >1 or bone metastasis, but a benefit for patients with M1c stage. | ||
| 650 | 4 | |a bone metastases | |
| 650 | 4 | |a cancer registry | |
| 650 | 4 | |a KEYNOTE 189 | |
| 650 | 4 | |a mNSCLC | |
| 650 | 4 | |a real world data | |
| 700 | 1 | |a Herth, Felix |e VerfasserIn |0 (DE-588)1016095236 |0 (DE-627)705477568 |0 (DE-576)351509925 |4 aut | |
| 700 | 1 | |a Kokh, Daria B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Morakis, Philipp |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pulmonology |d London : Taylor & Francis, 2018 |g 31(2025), 1, Artikel-ID 2457856, Seite 1-11 |h Online-Ressource |w (DE-627)1691013218 |w (DE-600)3009651-0 |x 2531-0437 |7 nnas |a Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC Real-world evidence |
| 773 | 1 | 8 | |g volume:31 |g year:2025 |g number:1 |g elocationid:2457856 |g pages:1-11 |g extent:11 |a Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC Real-world evidence |
| 856 | 4 | 0 | |u https://doi.org/10.1080/25310429.2025.2457856 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250724 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1016095236 |a Herth, Felix |m 1016095236:Herth, Felix |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PH1016095236 |e 950000PH1016095236 |e 950900PH1016095236 |e 50000PH1016095236 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN1931722919 |e 4749478008 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"recId":"1691013218","type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["Volume 24, issue 1 (2018)-"],"disp":"Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC Real-world evidencePulmonology","part":{"pages":"1-11","volume":"31","extent":"11","year":"2025","issue":"1","text":"31(2025), 1, Artikel-ID 2457856, Seite 1-11"},"id":{"eki":["1691013218"],"zdb":["3009651-0"],"issn":["2531-0437"]},"origin":[{"publisherPlace":"London ; Amsterdam","dateIssuedDisp":"[2018]-","publisher":"Taylor & Francis ; Elsevier"}],"title":[{"title":"Pulmonology","title_sort":"Pulmonology"}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"name":{"displayForm":["Sociedade Portuguesa de Pneumologia"]}}],"person":[{"display":"Surovtsova, Irina","family":"Surovtsova","role":"aut","given":"Irina"},{"given":"Felix","family":"Herth","display":"Herth, Felix","role":"aut"},{"family":"Kokh","display":"Kokh, Daria B.","role":"aut","given":"Daria B."},{"role":"aut","display":"Morakis, Philipp","family":"Morakis","given":"Philipp"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"05 Feb 2025"}],"recId":"1931722919","id":{"doi":["10.1080/25310429.2025.2457856"],"eki":["1931722919"]},"note":["Gesehen am 24.07.2025"],"name":{"displayForm":["Irina Surovtsova, Felix J.F. Herth, Daria B. Kokh and Philipp Morakis"]},"title":[{"title_sort":"Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC","title":"Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC","subtitle":"Real-world evidence"}],"language":["eng"],"physDesc":[{"extent":"11 S.","noteIll":"Illustrationen"}]} | ||
| SRT | |a SUROVTSOVAOUTCOMESOF0520 | ||